All Releases
 |
VIVUS to Present at Barclays Capital 2010 Global Healthcare Conference
Mar 19, 2010
|
8.5 KB |
|
| |
MOUNTAIN VIEW, Calif., March 19, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Barclays Capital 2010 Global Healthcare Conference.
The VIVUS presentation will take place at the Loews Miami Beach Hotel in Miami, FL ...
|
|
VIVUS Reports 2009 Fourth Quarter and Full-Year Financial Results
Mar 8, 2010
|
19.9 KB |
|
| |
MOUNTAIN VIEW, Calif., March 8, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today reported its financial results for the fourth quarter and year ended December 31, 2009.
"This past year was transformational for VIVUS given the significant achievements in both the Qnexa and avanafil investigational product programs, whic...
|
|
VIVUS Announces the Issuances of Three Additional Qnexa(R) Patents
Mar 8, 2010
|
11.0 KB |
|
| |
MOUNTAIN VIEW, Calif., March 8, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth ...
|
|
VIVUS to Present at Two Upcoming Investor Conferences
Mar 3, 2010
|
9.3 KB |
|
| |
MOUNTAIN VIEW, Calif., March 3, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc.
(Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer,
will present an overview of the company at two investment conferences during
the month of March.
The conference presentation schedule is as follows:
Cowen and Com...
|
|
VIVUS Announces Date of Fourth Quarter and Full Year 2009 Financial Results and Conference Call
Mar 2, 2010
|
10.1 KB |
|
| |
MOUNTAIN VIEW, Calif, Mar 2, 2010 (GlobeNewswire via COMTEX News Network) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the fourth quarter and year ended December 31, 2009 after the NASDAQ Market cl...
|
|
VIVUS Announces FDA Acceptance of Qnexa(R) New Drug Application for Treatment of Obesity
Mar 1, 2010
|
11.7 KB |
|
| |
MOUNTAIN VIEW, Calif., March 1, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for its investigational drug, Qnexa(R), for the treatment of obesity. The target date for the FDA to complete its ...
|
|
VIVUS to Present at the BIO CEO and Investor Conference
Feb 4, 2010
|
8.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Dr. Charles Bowden, senior director, clinical development, will present an overview of the company at the 12th Annual BIO CEO and Investor Conference.
The VIVUS presentation will take place at the Waldorf Astoria Hotel in Ne...
|
|
VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 Minutes
Jan 11, 2010
|
13.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS,Inc. (Nasdaq: VVUS) today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED). Patients who attempted intercourse within 15 minutes ...
|
|
VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea
Jan 7, 2010
|
16.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 07, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa(R), an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treat...
|
|
VIVUS To Host Conference Call and Webcast Discussion of Results From Phase 2 Study of Qnexa(R) in Obstructive Sleep Apnea
Jan 6, 2010
|
10.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from a phase 2 study evaluating the safety and efficacy of Qnexa, for the treatment of obstructive sleep apnea (OSA), on January 7th prior to market open. The announcement will be followed by a webcast and conferenc...
|
|
VIVUS to Present at the 2010 JP Morgan Healthcare Conference
Jan 5, 2010
|
8.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 05, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 28th Annual JP Morgan Healthcare Conference.
The VIVUS presentation will take place at the Westin St. Francis Hotel in San Franc...
|
|
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Dec 29, 2009
|
13.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food an...
|
|
VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile
Nov 18, 2009
|
18.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS,Inc. (Nasdaq: VVUS) today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. The REVIVE s...
|
|
VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Nov 17, 2009
|
8.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.
Conference Call...
|
|
VIVUS to Present at Lazard Capital Markets Healthcare Conference
Nov 11, 2009
|
8.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference.
The VIVUS presentation will take place at The St. Regis in New York, N...
|
|
VIVUS To Present at Merriman Curhan Ford's Investor Summit
Nov 5, 2009
|
8.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at Merriman Curhan Ford's 6th Annual Investor Summit.
The VIVUS presentation will take place at the Hotel Sofitel in New York, NY on Tu...
|
|
VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Nov 3, 2009
|
17.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS,Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its highlights and financial results for the third quarter ended September 30, 2009.
Third Quarter HighlightsIn...
|
|
VIVUS Announces Promotion of Peter Tam to President
Nov 3, 2009
|
10.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS,Inc. (Nasdaq: VVUS) today announced the promotion of Peter Tam to president of VIVUS. In this position, Mr. Tam will lead and have overall responsibility for VIVUS' development and business functions, including corporate and product strategy, business develo...
|
|
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Oct 29, 2009
|
18.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of ...
|
|
VIVUS Announces Date of Third Quarter 2009 Financial Results and Conference Call
Oct 28, 2009
|
9.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 28, 2009 (GlobeNewswire via COMTEX News Network) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the third quarter ended September 30, 2009 after the NASDAQ Market closes on...
|
|
|
= add release to Briefcase |
Shareholder Briefcase
Email Alerts
Download Library
RSS News Feeds